Game-changing cholesterol-buster further reduces heart attack, stroke April 16, 2017 By Tracey Walker A new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%. Five advancements in diabetes treatment to watch April 10, 2017 By Karen Appold The healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients. New therapies show promise in treating diabetes New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes. Insurer's foundation heart initiative addresses cardiovascular disparities November 27, 2016 By Tracey Walker The Independence Blue Cross Foundation Healthy Hearts Initiative aims to improve survival rates for sudden cardiac arrest, increase CPR preparedness. Cardiovascular drugs: Current spending, future outlook May 06, 2016 By Tracey Walker Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population. Top 3 cardiovascular patient compliance challenges April 27, 2016 By Karen Appold Staying compliant with a prescribed treatment regimen gives cardiovascular disease patients the best chance of improving their heart health and reducing future incidences of cardiac events. Here’s how to get patients on board. Driving down heart disease costs: Tips for plans, providers April 25, 2016 By Karen Appold Heart disease takes a heavy toll on the healthcare system, but promising new treatments are emerging Telemonitoring of heart failure patients reduces readmissions April 21, 2016 By Tracey Walker Study demonstrates how new technology can drive higher value healthcare for heart failure patients. Heart drug improves life expectancy January 14, 2016 By Christine Blank There is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine. Takeda announces post hoc analysis of data from EXAMINE cardiovascular safety outcomes trial March 13, 2015 By Tracey Walker In patients with type 2 diabetes and recent acute coronary syndrome (ACS), dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin compared to placebo did not increase the risk of heart failure (HF) outcomes, according to data published in The Lancet.